Buparlisib (codenamed AN2025 and BKM120) is an experimental anti-cancer medication. It is a small molecule orally-available pan-class I phosphoinositide 3-kinase (PI3K) inhibitor.[1] Buparlisib was under investigation as a treatment for advanced breast cancer but was abandoned due to negative results. It is still under investigation as a potential treatment for head and neck squamous cell carcinoma (HNSCC).
Clinical data | |
---|---|
Other names | AN2025, BKM120 |
ATC code |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
CompTox Dashboard (EPA) |
|
ECHA InfoCard | 100.232.248 |
Chemical and physical data | |
Formula | C18H21F3N6O2 |
Molar mass | 410.401 g·mol−1 |
3D model (JSmol) |
|
| |
|
Buparlisib was under investigation as a treatment for advanced or metastatic HER2-negative breast cancer in several phase III clinical trials:
These results led the trials' sponsor, Novartis, to cancel their breast cancer study program with buparlisib.
Buparlisib is still under investigation as a potential treatment for head and neck squamous cell carcinoma (HNSCC) in the ongoing phase III trial BURAN, which compares buparlisib + paclitaxel to paclitaxel alone in patients with recurrent or metastatic HNSCC. Results are expected for December 2022.[8]